CM
CAPR icon

Caption Management’s Capricor Therapeutics CAPR Stock Holding History

Caption Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-140,000
Closed -$1.48M – 1479
2025
Q1 		$1.33M Buy
+140,000
New +$1.94M 0.01% 821

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Caption Management's CAPR Position: Q2 2025 in Review

Caption Management sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 140,000 shares — an estimated $1.48M sold.

Caption Management first reported a position in CAPR in Q1 2025 and held it in 1 quarter. The position peaked at $1.33M in Q1 2025. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

  • Caption Management reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 140,000 Capricor Therapeutics shares in Q2 2025, an estimated $1.48M.
  • Caption Management first reported a position in Capricor Therapeutics in Q1 2025 and held it in 1 quarter.
  • Caption Management's Capricor Therapeutics position peaked at $1.33M in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.